Device, method and system for implementing a physical area network for cancer immunotherapy

• US 10,265,017 B1
• Filed: 12/12/2018
• Issued: 04/23/2019
• Est. Priority Date: 12/12/2018
• Status: Active Grant

• Current Assignee: Lucas Myslinski
• Original Assignee: Lucas Myslinski
• Inventors: Myslinski, Lucas J.
• Primary Examiner(s): Pope, Daryl C
• Application Number:
  US16/217,358
• Time in Patent Office: 132 Days
• Field of Search: 3405391, 34053911, 34053913, 3405731
• CPC Class Codes: A61B 2562/0285 Nanoscale sensors
• CPC Class Codes: A61B 5/0024 for multiple sensor units attached to the patient, e.g. using a body or personal area network
• CPC Class Codes: A61B 5/065 Determining position of the probe employing exclusively positioning means located on or in the probe, e.g. using position sensors arranged on the probe
• CPC Class Codes: A61B 5/07 Endoradiosondes
• CPC Class Codes: A61B 5/4839 combined with drug delivery
• CPC Class Codes: A61B 5/6833 Adhesive patches
• CPC Class Codes: A61B 5/6861 Capsules, e.g. for swallowing or implanting
• CPC Class Codes: A61K 41/00 Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
• CPC Class Codes: A63F 13/212 using sensors worn by the player, e.g. for measuring heart beat or leg activity
• CPC Class Codes: A63F 13/23 for interfacing with the game device, e.g. specific interfaces between game controller and console
• CPC Class Codes: H04B 10/90 Non-optical transmission systems, e.g. transmission systems employing non-photonic corpuscular radiation
• CPC Class Codes: H04B 13/005 Transmission systems in which the medium consists of the human body

Abstract

A physical area network described herein enables significantly improved health monitoring and treatment by utilizing internal (in-body) mechanisms and information and external mechanisms and information.

Claims

1. A method of treating cancer comprising:

positioning, in or on a user, a physical area network comprising;

a first set of nano-nodes, wherein a surface of each nano-node in the first set of nano-nodes is encapsulated with one or more plasma membrane-associated components, and wherein the one or more plasma membrane-associated components are derived from a cancer cell;

a second set of nano-nodes;

at least one nano-router; and

at least one nano-micro interface, wherein each nano-node in the second set of nano-nodes includes a communication device to communicate with a nano-node of the second set of nano-nodes, the at least one nano-router and/or the at least one nano-micro interface; and

activating an immune response against the cancer cell in the user, thereby treating the cancer.

2. The method of claim 1 further comprising deploying a medication using the first set of nano-nodes, the second set of nano-nodes and/or a third set of nano-nodes.

3. The method of claim 2 wherein the first set of nano-nodes, the second set of nano-nodes, and/or the third set of nano-nodes include a plurality of chambers for storing a plurality of separate medications.

4. The method of claim 3 wherein the plurality of separate medications are inert components of a medication which are activated when mixed upon release.

5. The method of claim 1 further comprising communicating with a gaming system.

6. The method of claim 5 wherein communicating with the gaming system includes the physical area network communicating aspects of treating the cancer wherein the aspects of treating the cancer are used in gameplay of the gaming system, and communicating with the gaming system includes the gaming system communicating gameplay information to the physical area network which is used in treating the cancer.

7. The method of claim 1 wherein positioning the physical area network includes utilizing nano-nodes capable of autonomous movement.

8. The method of claim 1 wherein positioning the physical area network includes including a magnetic component in the first set of nano-nodes and/or the second set of nano-nodes which are attracted by a magnetic device.

9. The method of claim 1 wherein communicating with the communication device utilizes terahertz communication.

10. The method of claim 1 wherein communicating with the communication device utilizes in vivo communication and accounts for a transmission medium when sending a communication.

11. The method of claim 1 wherein communicating with the communication device determines a shortest path between a starting device and an end device.

12. The method of claim 1 wherein communicating with the communication device utilizes a family identifier to identify which nano-nodes with which to communicate.

13. The method of claim 1 wherein communicating with the communication device utilizes DNA encryption.

14. The method of claim 1 wherein communicating with the communication device includes translating from a first language to a second language.

15. The method of claim 1 wherein communicating with the communication device does not utilize encryption, and communicating with the nano-micro interface uses encryption.

16. The method of claim 1 wherein each nano-node of the second set of nano-nodes includes one or more sensors.

17. The method of claim 1 wherein positioning the physical area network is based on detecting DNA methylation.

18. A system comprising:

a first set of nano-nodes, wherein a surface of each nano-node in the first set of nano-nodes is encapsulated with one or more plasma membrane-associated components, and wherein the one or more plasma membrane-associated components are derived from a cancer cell;

a second set of nano-nodes;

at least one nano-router; and

at least one nano-micro interface, wherein each nano-node in the second set of nano-nodes includes a communication device to communicate with a nano-node of the second set of nano-nodes, the at least one nano-router and/or the at least one nano-micro interface.

19. A composition comprising:

a nano-node, wherein the nano-node surface is encapsulated with one or more plasma membrane-associated components, and wherein the one or more plasma membrane-associated components are derived from a cancer cell, wherein the nano-node further includes a plurality of chambers, each chamber for storing a medication, wherein the nano-node further includes an antenna configured for communicating with another nano-node, a nano-router and/or a nano-micro interface, wherein the nano-node further includes a coupling mechanism configured for coupling to a user to enable in vivo communication using a user'"'"'s body for communication.

20. The composition of claim 19, wherein the plasma membrane-associated components comprise a lipid, a protein, or a carbohydrate, wherein the nano-node is 10-100 nm in size, wherein the nano-node comprises a polymeric nano-node, and wherein the one or more plasma membrane-associated components generate a plasma membrane that is approximately 5 nm thick.